ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does METX (METX) operate in?
METX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is METX (METX) current stock price?
As of the latest data, METX stock price is CA$2.50, with a previous close of CA$2.50.
What is METX (METX) current market capitalization?
METX market cap is approximately 75.12 million.
What is METX (METX) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.04.
Does METX (METX) pay dividends?
No. METX does not pay a dividend.
What is METX (METX) beta (volatility) score?
METX has a beta of 0.050, indicating lower volatility than the overall market.
